A phase IV open- label, randomized and pilot clinical trial, designed to evaluate the potential neurotoxicity of dolutegravir/lamivudine/abacavir in neurosymptomatic HIV patients and their reversibility after switching to elvitegravir/cobicistat/emtricitabina/tenofovir alafenamide
Latest Information Update: 27 Jan 2020
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Abacavir/dolutegravir/lamivudine
- Indications HIV infections
- Focus Adverse reactions
- Acronyms DREAM study
- 26 May 2019 Status changed from recruiting to completed.
- 30 Jun 2017 New trial record